Form D · Pharmaceuticals
Microbion Corp
Bozeman, MT · CIK 0001318639
Offering snapshot reported Jul 27, 2021 · SEC filing
- Reported sold
- $11.9M Offering amount: $13.4M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 8, 2021 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$4,106,048 → $11,890,627
- Reported investors15 → 18
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 27, 2021 | Amendment | $11,890,627 | $7,784,579vs Mar 31, 2021 | 18 | SEC filing |
| Mar 31, 2021 | Amendment | $4,106,048 | $2,106,049vs Jan 25, 2021 | 15 | SEC filing |
| Jan 25, 2021 | Initial | $1,999,999 | No comparison | 1 | SEC filing |
| Jan 13, 2017 | Initial | $25,373,967 | No comparison | 11 | SEC filing |
| Jan 22, 2016 | Amendment | $5,861,141 | $2,518,074vs Jan 21, 2015 | 33 | SEC filing |
| Jan 21, 2015 | Amendment | $3,343,067 | $3,243,067vs Jan 22, 2014 | 19 | SEC filing |
| Jan 22, 2014 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Apr 3, 2013 | Amendment | $1,246,025 | $1,021,029vs Oct 26, 2012 | 19 | SEC filing |
| Oct 26, 2012 | Initial | $224,996 | No comparison | 4 | SEC filing |
| Sep 15, 2011 | Amendment | $932,664 | $733,290vs Aug 11, 2010 | 22 | SEC filing |
| Aug 11, 2010 | Initial | $199,374 | No comparison | 4 | SEC filing |
| Nov 9, 2009 | Initial | $414,000 | No comparison | 12 | SEC filing |
| Dec 10, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 10, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 10, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 6, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Oct 18, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Sep 14, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| May 16, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 18, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-387205
The amount sold includes outstanding principal and accrued and unpaid interest on outstanding debt which converted.
Source: Form D, filed Jul 27, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Zafrira Avnur | Director |
| Brett Baker | Director, Executive |
| Jared Carney | Director |
| Tom Farquhar | Director |
| Robert Gillam | Director |
| Jason Harmon | Director |
| Frank Kerins | Executive |
| Roger Kuypers | Director |
| Karim Lalji | Director |
| Julia Levy | Director |
| Rodger May | Director |
| Donald Rix | Director |
| Steven Schellong | Director |
| Jarret Sha | Director |
| Kaley Wilson | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
5 West Mendenhall Street Suite 202
Bozeman, MT, 59715
Bozeman, MT, 59715